InsidersTradesSigma
Personalis, Inc. Stock: price and directors' dealings · United States · SEC (Form 4)
Follow the Personalis, Inc. share price and the full management transaction log of the company, a listed issuer based in United States. Shares are quoted on US US, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Personalis, Inc. has published 79 insider filings. Market capitalisation: €1.4bn. The latest transaction was reported on 14 May 2026 (Attribution). Among the most active insiders: Chen Richard. The full history is free.
79
Insider Decl.
0
Thresholds
€15,456
1 ops.
Buy Volume
€460,739
59 ops.
Sell Volume
48Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 23,759 of 25,791 companies
19.7
score / 100
Value21
Quality19
FCF yld-5.4%
Earn yld-5.5%
EV/EBITDA·
ROE-41%
Gross mgn23%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 14 May 2026
Declarations79 total
6,250 shares0Common StockSEC:0001231845-26-000001
6,250 shares0Common StockSEC:0001471716-26-000001
6,250 shares0Common StockSEC:0001243399-26-000001
6,250 shares0Common StockSEC:0001008891-26-000001
910 shares@ US$4.954.3% of flowCommon StockSEC:0001415889-25-013846:0
1,291 shares@ US$4.953.6% of flowCommon StockSEC:0001415889-25-013848:0
1,675 shares@ US$4.9512.5% of flowCommon StockSEC:0001415889-25-013847:0
708 shares@ US$5.792.5% of flowCommon StockSEC:0001415889-25-002398:0
519 shares@ US$5.793.0% of flowCommon StockSEC:0001415889-25-002386:0
6,865 shares@ US$3.8215.8% of flowCommon StockSEC:0001415889-24-029736:0
4,834 shares@ US$3.8218.6% of flowCommon StockSEC:0001415889-24-029741:0
1,513 shares@ US$3.829.3% of flowCommon StockSEC:0001415889-24-029739:0
1,307 shares@ US$3.793.0% of flowCommon StockSEC:0001415889-24-027347:0
1,693 shares@ US$3.7910.3% of flowCommon StockSEC:0001415889-24-027343:0
921 shares@ US$3.793.5% of flowCommon StockSEC:0001415889-24-027338:0
26,443 shares@ US$5.3887.9% of flowCommon StockSEC:0001415889-24-026124:0
4,609,400 shares@ US$1.50100.0% of flowCommon StockSEC:0001493152-24-033271:0
524 shares@ US$2.971.5% of flowCommon StockSEC:0001415889-24-020534:0
742 shares@ US$2.971.3% of flowCommon StockSEC:0001415889-24-020533:0
5,055 shares@ US$1.296.4% of flowCommon StockSEC:0001415889-24-017684:0
7,176 shares@ US$1.295.4% of flowCommon StockSEC:0001415889-24-017683:0
1,585 shares@ US$1.293.2% of flowCommon StockSEC:0001415889-24-017682:0
1,333 shares@ US$1.381.1% of flowCommon StockSEC:0001415889-24-014040:0
940 shares@ US$1.381.3% of flowCommon StockSEC:0001415889-24-014041:0
1,731 shares@ US$1.383.7% of flowCommon StockSEC:0001415889-24-014039:0
25 of 79 declarations
About Personalis, Inc.
Personalis, Inc. (ticker: PSNL) is a U.S.-listed company trading on the NASDAQ in the United States. It operates in the intersection of cancer genomics, molecular diagnostics, and precision oncology. Founded in 2011 by a team of next-generation sequencing thought leaders from Stanford University, the company began operations that same year and has since built a niche position in advanced genomic testing for cancer. Its headquarters, which also house a CLIA-certified and CAP-accredited laboratory, are located in Fremont, California. Personalis’ business model is anchored in two main pillars. First, it develops and commercializes comprehensive tumor-profiling solutions for laboratories, clinicians, and biopharma partners. Its flagship ImmunoID NeXT platform is designed to provide a multidimensional view of the tumor microenvironment from a single tissue sample, combining exome, transcriptome, and immune-biomarker data. Second, the company has expanded into liquid biopsy through NeXT Personal, a tumor-informed assay designed to detect minimal residual disease, monitor treatment response, and track recurrence with very high sensitivity. Personalis also offers NeXT Dx, a comprehensive genomic profiling test intended to help physicians identify actionable therapies or suitable clinical trials. From a competitive standpoint, Personalis differentiates itself through a highly integrated cancer genomics approach and a particularly broad molecular readout. That positions it against other oncology diagnostics and sequencing specialists, but its competitive advantage lies in analytical depth, clinical orientation, and strong ties to pharmaceutical partners. Its customer base includes pharma and biopharma companies, diagnostics firms, universities, non-profit organizations, government entities, and cancer patients. Recent highlights include the company’s 2025 quarterly and full-year reporting cycle, which emphasized continued commercialization of NeXT Personal and ongoing expansion in clinical and research use cases. Personalis has also announced scientific publications validating test performance, as well as a commercial partnership with Myriad Genetics to broaden access to biopharma customers. For French-speaking investors, PSNL remains an innovative healthcare name exposed to the structural growth of biomarker-driven oncology and molecular testing, but still dependent on clinical adoption, reimbursement progress, and biopharma contract execution.
